Indivior declares USD 8.13 dividend. Indivior stock gains 1.27 percent

Published on 10/02/2026 at 14:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue hit USD 343.00 million, up 14.00 percent year over year. Indivior stock costs EUR 31.90 on October 2, 2026, versus EUR 31.50.

Moderne Pharma-Produktionsanlage mit Glasfassade und Industrieanlagen im Tageslicht — Indivior PLC mit ISIN GB00BYZ0C031 betreibt moderne Pharma-Produktionsanlage für innovative Suchtmedizin-Präparate weltweit an Patienten, Illustration mit AI erstellt.

Indivior (ISIN US45579U1097) was trading at EUR 31.90 at Lang & Schwarz on October 2, 2026 at 2:33 p.m. CEST, up 1.27 percent versus the EUR 31.50 prior close. On September 17, 2026, Nasdaq reported that Indivior declared a conditional USD 8.13 special cash dividend per share.

Dividend depends on merger closing

The dividend is payable to holders of record on October 30, 2026, but only if Indivior completes its planned merger with Supernus Pharmaceuticals. The payment is anticipated on November 6, 2026, while Supernus shareholders will not receive the dividend on Indivior shares issued as merger consideration, according to the SEC filing dated September 17, 2026.

The condition gives the payout a direct transaction risk: the filing states that Indivior will not pay the dividend if the merger is not completed. That structure makes the record date important, but it does not remove the closing requirement.

Second-quarter revenue rises 14.00 percent

Indivior reported USD 343.00 million of total net revenue for the second quarter of 2026, up 14.00 percent from the prior-year quarter. SUBLOCADE revenue reached USD 253.00 million, a 21.00 percent year-over-year increase, according to StockTitan.

Adjusted EBITDA climbed 111.00 percent year over year to USD 186.00 million, while the adjusted EBITDA margin expanded to 54.00 percent from 29.00 percent. GAAP net income was USD 122.00 million in the second quarter, and management raised full-year 2026 net revenue guidance to USD 1.295-1.365 billion from USD 1.215-1.285 billion.

Stock remains below its yearly high

Indivior's market capitalization was USD 4.4 billion as of October 1, 2026. Its primary Nasdaq listing showed a 52-week range of USD 22.56 to USD 42.81, placing the current U.S. quote below the yearly high while the euro quote provides the reference for German investors.

Trading reference for October 2

At Lang & Schwarz, Indivior was trading at EUR 31.90 on October 2, 2026 at 2:33 p.m. CEST, plus 1.27 percent versus the prior close of EUR 31.50 on October 1, 2026. The further course of trading is shown by the continuously updated real-time quote of Indivior stock.